Cevidoplenib
Immune Thrombocytopenia (ITP)
Phase not specifiedActive
Key Facts
About Genosco
Genosco is a U.S.-based, clinical-stage biotech founded in 2018 with a core focus on kinase-targeted therapies. The company's differentiation lies in its proprietary discovery platform, GENO-K™/GENO-D™, designed to identify rare kinase sequences and develop selective inhibitors and protein degraders. Its pipeline includes both internally discovered assets and partnered programs, with lead candidates like a ROCK2 inhibitor entering Phase 1 and a legacy asset, lazertinib, already approved in combination therapies. The company appears to be a subsidiary of Oscotec Inc. and operates with a mix of independent R&D and strategic partnerships.
View full company profileTherapeutic Areas
Other Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| SAR443820 (Rilzabrutinib) | Sanofi | Phase 3 |